Reviewer's report

Title: Efficacy and safety of fluticasone furoate 100 ug and 200 ug once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study

Version: 3 Date: 27 March 2014

Reviewer: Vanessa Murphy

Reviewer's report:

This paper outlines a descriptive study of the efficacy and safety of 100ug or 200 ug of fluticasone furoate once daily for moderate-severe persistent asthma. Improvements in FEV1 were observed in both groups from baseline and no safety concerns were identified.

Minor essential revisions:
The authors indicate that one study centre was removed from the ITT analysis due to concerns with quality of data collection. This would seem to be contrary to the point of ITT analysis. Could further explanation be given as to the suitability of removing a study centre in this way? How many participants were removed? How were the results affected if this centre’s results remained? What specific concerns were there about the quality of data collected at this site?

Why was a group using Fluticasone propionate or another drug / dosing regimen (such as twice daily) not used as a “control” group?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests